ALIF-B Stock Analysis: AddLife (publ) | ST
Medical Instruments & Supplies | ST, Sweden | Market Cap: 22.216m SEK | 12M Return: -6.3% | SE0014401378 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 28.3M
EPS Trend: 88.0%
Qual. Beats: 0
Rev. Trend: 92.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AddLife AB (publ), founded in 1906 and headquartered in Stockholm, Sweden, is a distributor of instruments, equipment, consumables, and reagents serving medical care, research, academic institutions, and the food and pharmaceutical industries. The company operates through two business segments: Labtech and Medtech.
The Labtech segment supplies analytical instruments, microscopes, consumables, reagents, software support, and technical services across diagnostics, biomedical research, laboratory analysis, microbiology, clinical chemistry, coagulation, molecular biology, immunology, point-of-care testing, and veterinary diagnostics. It also offers customer training programs. The Medtech segment provides medical device products and assistive solutions spanning surgery, orthopaedics, critical care, endoscopy, wound care, healthcare IT, ophthalmology, home adaptation, welfare technology, and technical aids for elderly and disabled users.
AddLife conducts business across more than a dozen European markets, including Sweden, the UK, Ireland, Spain, the Nordic and DACH regions, Italy, and Poland, with additional international activity. As a distributor in the Life Sciences Tools & Services sub-industry, the company combines one-time equipment sales with recurring revenue from consumables and reagents, which are typically replenished frequently by laboratory and clinical customers.
- Labtech segment growth accelerates on diagnostics and biomedical research demand
- Medtech margins face pressure from European healthcare budget tightening
- M&A strategy continues expanding European medical device footprint
| Net Income: 644.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 1.02 > 1.0 |
| NWC/Revenue: -22.03% < 20% (prev -1.12%; Δ -20.91% < -1%) |
| CFO/TA 0.10 > 3% & CFO 1.39b > Net Income 644.0m |
| Net Debt (5.17b) to EBITDA (1.65b): 3.14 < 3 |
| Current Ratio: 0.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.9m) vs 12m ago 0.0% < -2% |
| Gross Margin: 38.67% > 18% (prev 37.81%; Δ 0.86% > 0.5%) |
| Asset Turnover: 81.40% > 50% (prev 83.15%; Δ -1.75% > 0%) |
| Interest Coverage Ratio: 4.72 > 6 (EBIT TTM 831.0m / Interest Expense TTM 176.0m) |
| A: -0.17 (Total Current Assets 4.33b - Total Current Liabilities 6.69b) / Total Assets 13.6b |
| B: 0.18 (Retained Earnings 2.48b / Total Assets 13.6b) |
| C: 0.06 (EBIT TTM 831.0m / Avg Total Assets 13.1b) |
| D: 0.78 (Book Value of Equity 5.95b / Total Liabilities 7.67b) |
| Altman-Z'' = 0.70 = B |
| DSRI: 1.00 (Receivables 1.92b/1.89b, Revenue 10.7b/10.5b) |
| GMI: 0.98 (GM 37.81% / 38.67%) |
| AQI: 0.98 (AQ_t 0.59 / AQ_t-1 0.60) |
| SGI: 1.02 (Revenue 10.7b / 10.5b) |
| TATA: -0.05 (NI 644.0m - CFO 1.39b) / TA 13.6b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of November 05, 2026, the stock is trading at SEK 184.50 with a total of 776,966 shares traded. Over the past week, the price has changed by +1.15%, over one month by +7.45%, over three months by +12.64% and over the past year by -6.32%.
Current recommended Stop Loss: 171.60 (which is 7% or 2.7 ATR below the current price).
AddLife (publ) has no consensus analysts rating.
P/E Trailing = 34.592
P/S = 2.0766
P/B = 3.7067
Revenue TTM = 10.7b SEK
EBIT TTM = 831.0m SEK
EBITDA TTM = 1.65b SEK
Long Term Debt = 516.0m SEK (from longTermDebt, last quarter)
Short Term Debt = 4.62b SEK (from shortTermDebt, last quarter)
Debt = 5.64b SEK (from shortLongTermDebtTotal, last quarter) + Leases 504.0m
Net Debt = 5.17b SEK (calculated: Debt 5.64b - CCE 477.0m)
Enterprise Value = 27.4b SEK (22.2b + Debt 5.64b - CCE 477.0m)
Interest Coverage Ratio = 4.72 (Ebit TTM 831.0m / Interest Expense TTM 176.0m)
EV/FCF = 24.32x (Enterprise Value 27.4b / FCF TTM 1.13b)
FCF Yield = 4.11% (FCF TTM 1.13b / Enterprise Value 27.4b)
FCF Margin = 10.53% (FCF TTM 1.13b / Revenue TTM 10.7b)
Net Margin = 6.02% (Net Income TTM 644.0m / Revenue TTM 10.7b)
Gross Margin = 38.67% ((Revenue TTM 10.7b - Cost of Revenue TTM 6.56b) / Revenue TTM)
Gross Margin QoQ = 38.44% (prev 39.47%)
Tobins Q-Ratio = 2.01 (Enterprise Value 27.4b / Total Assets 13.6b)
Interest Expense / Debt = 3.12% (Interest Expense 176.0m / Debt 5.64b)
Taxrate = 27.74% (248.0m / 894.0m)
NOPAT = 600.5m (EBIT 831.0m * (1 - 27.74%))
Current Ratio = 0.65 (Total Current Assets 4.33b / Total Current Liabilities 6.69b)
Debt / Equity = 0.95 (Debt 5.64b / totalStockholderEquity, last quarter 5.95b)
Debt / EBITDA = 3.14 (Net Debt 5.17b / EBITDA 1.65b)
Debt / FCF = 4.59 (Net Debt 5.17b / FCF TTM 1.13b)
Total Stockholder Equity = 5.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.90% (Net Income 644.0m / Total Assets 13.6b)
RoE = 11.32% (Net Income TTM 644.0m / Total Stockholder Equity 5.69b)
RoCE = 13.40% (EBIT 831.0m / Capital Employed (Equity 5.69b + L.T.Debt 516.0m))
RoIC = 5.42% (NOPAT 600.5m / Invested Capital 11.1b)
WACC = 6.33% (E(22.2b)/V(27.9b) * Re(7.36%) + D(5.64b)/V(27.9b) * Rd(3.12%) * (1-Tc(0.28)))
Discount Rate = 7.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -7.11 | Cagr: 0.00%
[DCF] Terminal Value 77.97% ; FCFF base≈1.04b ; Y1≈1.19b ; Y5≈1.76b
[DCF] Fair Price = 181.6 (EV 26.5b - Net Debt 5.17b = Equity 21.3b / Shares 117.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 88.05 | EPS CAGR: 85.16% | SUE: -0.18 | # QB: 0
Revenue Correlation: 92.18 | Revenue CAGR: 3.26% | SUE: 0.07 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=6.36 | Chg30d=+9.66% | Revisions=+40% | GrowthEPS=+74.2% | GrowthRev=+5.3%
EPS next Year (2027-12-31): EPS=7.75 | Chg30d=+9.31% | Revisions=+40% | GrowthEPS=+21.9% | GrowthRev=+8.7%
[Analyst] Revisions Ratio: +57% (up=4, down=0)